ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Best’s Special Report: Challenges to Medicare Advantage Led to $5.7 Billion Underwriting Loss in 2024

Higher utilization since 2023 led to $5.7 billion underwriting loss for the Medicare Advantage line of business in 2024, following gains in at least the preceding five years, according to a new AM Best report.

The Best’s Special Report, “Challenges to Medicare Advantage Will Negatively Impact Profitability,” notes that Medicare Advantage had been a reliable source of earnings for the U.S. health insurance industry, contributing to overall profitability. Underwriting gains from Medicare Advantage made up approximately 40% of underwriting gains from 2019 to 2022, but that decreased to 20% in 2023 before the 2024 underwriting loss. Overall, nearly three-quarters of companies with a concentration in Medicare Advantage business reported an underwriting loss for the line in 2024.

“Medicare Advantage enrollment and premium continue to grow as more people are aging into the program. However, plans have experienced an increase in utilization and medical trends that have persisted longer than expected,” said Jason Hopper. “Changes to the risk-adjustment payment model by the Center for Medicare and Medicaid Services, as well as lower Star Ratings across the industry, also have contributed to recent underwriting losses.”

The report states that in 2025, the number of companies (aggregated by ultimate parent) that had contracts with Star Ratings of four or higher had dropped by more than 25% when compared with 2022. The largest declines were seen among publicly traded and Blue Cross/Blue Shield companies.

“Profitability will most likely continue to be under pressure due to the following reasons: utilization and medical costs are up; medical inflation consistently outpaces the consumer price index; individuals are receiving more medical services, and some treatments are very expensive, such as gene therapy. AM Best expects health insurers to evaluate their position in the Medicare Advantage market for 2026,” said Bridget Maehr, director, AM Best.

To access the full copy of this special report, please visit http://www3.ambest.com/bestweek/purchase.asp?record_code=358200.

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2025 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.